更新于：2024-06-23
Cefazolin Sodium
头孢唑林钠
更新于：2024-06-23
概要
基本信息
原研机构 |
非在研机构 |
最高研发阶段批准上市 |
首次获批日期 美国 (1973-10-04), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看首次获批时间轴
结构
分子式C14H24N8NaO9S3 |
InChIKeyCQCPLXCVNXNUCK-HGUWTHONSA-N |
CAS号115850-11-8 |
关联
148
项与 头孢唑林钠 相关的临床试验Optimizing the Diagnostic Approach to Cephalosporin Allergy Testing
Preoperative Daptomycin Prophylaxis for Preventing Gram-Positive or Methicillin-Resistant Staphylococcus Aureus Infection in Two-Stage Exchange Arthroplasty: A Prospective, Randomized, Double-Blinded Trial
Investigation of hyper-excretion of cefazolin as a potential cause of treatment failure in patients with invasive bacterial infection
100 项与 头孢唑林钠 相关的临床结果
登录后查看更多信息
100 项与 头孢唑林钠 相关的转化医学
登录后查看更多信息
100 项与 头孢唑林钠 相关的专利（医药）
登录后查看更多信息
5,646
项与 头孢唑林钠 相关的文献（医药）2024-06-01Journal of clinical anesthesia
Examining cefazolin utilization and perioperative anaphylaxis in patients with and without a penicillin allergy label: A cross-sectional study
Article
作者: Hensley, Nadia B ; Murphy, Zachary R ; Massih, Sandra A ; Blumenthal, Kimberly G ; Klein, Eili Y ; Alvarez-Arango, Santiago ; Fabre, Valeria ; Muzaffar, Anum F ; Dispenza, Melanie C
STUDY OBJECTIVE:
To compare the occurrence of cefazolin perioperative anaphylaxis (POA) in patients with and without a penicillin allergy label (PAL) to determine whether the prevalence of cefazolin POA differs based on the presence of a PAL.
DESIGN:
Cross-sectional study.
SETTING:
A large U.S. healthcare system in the Baltimore-D.C. region, July 2017 to July 2020.
PATIENTS:
112,817 surgical encounters across inpatient and outpatient settings in various specialties, involving 90,089 patients. Of these, 4876 (4.3%) encounters had a PAL.
INTERVENTIONS:
Perioperative cefazolin administration within 4 h before surgery to 4 h after the procedure began.
MEASUREMENTS:
The primary outcome was cefazolin POA in patients with and without PALs. Potential POA cases were identified based on tryptase orders or diphenhydramine administrations within the initial cefazolin administration to 6 h postoperatively. Verification included two validation steps. The first checked for hypersensitivity reaction (HSR) documentation, and the second, led by Allergy specialists, identified POA and the probable culprit. The secondary outcome looked at cefazolin use trends in patients with a PAL, stratified by setting and specialty.
MAIN RESULTS:
Of 112,817 encounters, 1421 (1.3%) had possible cefazolin HSRs. Of these, 22 (1.5%) had POA, resulting in a 0.02% prevalence. Of these, 13 (59.1%) were linked to cefazolin and 9 (40.9%) attributed to other drugs. Only one cefazolin POA case had a PAL, indicating no significant difference in cefazolin POA prevalence between patients with and without PALs (p = 0.437). Perioperative cefazolin use in patients with PALs steadily increased from 2.6% to 6.0% between 2017 and 2020, specifically in academic settings.
CONCLUSIONS:
The prevalence of cefazolin POA does not exhibit significant differences between patients with and without PALs, and notably, the incidence remains remarkably low. Based on these findings, it is advisable to view cefazolin as an acceptable choice for prophylaxis in patients carrying a PAL.
2024-05-01Transplantation
Risk Factors for Surgical-site Infections After Liver Transplant: Does Perioperative Antibiotic Regimen Matter?
Article
作者: Rolak, Stacey C ; Yang, Liu ; Razi, Samrah ; Aqel, Bashar A ; Mahmood, Maryam ; Lahr, Brian D ; Yetmar, Zachary A ; Watt, Kymberly ; Beam, Elena
Background.:
Surgical-site infections (SSIs) are common in liver transplant recipients. The optimal SSI antimicrobial prophylaxis agent and duration are not established. We aimed to explore risk factors for SSIs after transplant, with a particular interest in the impact of perioperative antibiotic regimen on the development of SSIs.
Methods.:
Retrospective study of adults undergoing liver transplant across 3 transplant programs between January 1, 2020, and June 01, 2021.
Results.:
Of 557 patients included in the study, 32 (5.7%) were infected or colonized with a multidrug-resistant organism (MDRO) within 1 y before liver transplant. Narrow-spectrum SSI prophylaxis with ceftriaxone or cefazolin alone was administered in 488 of 577 patients (87.6%); the remaining 69 patients (12.4%) received broad-spectrum prophylaxis with vancomycin and aztreonam (n = 40), piperacillin–tazobactam (n = 11), carbapenems (n = 8), ceftriaxone and another antibiotic (n = 7), and others. Patients with pretransplant MDRO were more likely to receive broad-spectrum coverage than those without pretransplant MDROs (28.1% versus 11.4%, P = 0.005). SSIs were identified in 40 patients (7.2%); 25 (62.5%) were organ–space infections, 3 (7.5%) were deep incisional infections, and 12 (30.0%) were superficial incisional infections. The median time from liver transplant to SSIs was 14 d (interquartile range, 10–20.2). MDROs were identified in 12 SSIs (30%). Multivariable analysis revealed no significant association between antimicrobial spectrum and risk of SSIs (P = 0.5), whereas surgical leak (P<0.001) and reoperation (P = 0.017) were independently associated with increased risk of SSIs. SSIs were not significantly associated with composite risk of death or liver allograft failure.
Conclusions.:
The spectrum of antimicrobial prophylaxis did not impact the development of SSIs in liver transplant recipients.
2024-04-01Journal of shoulder and elbow surgery
Non-cefazolin antibiotic prophylaxis is associated with higher rates of elbow periprosthetic joint infection
Article
作者: Barlow, Jonathan ; Marigi, Erick ; Sanchez-Sotelo, Joaquin ; Morrey, Mark ; Rosenow, Christian ; Nieboer, Micah ; O'Driscoll, Shawn ; Tande, Aaron ; Braig, Zachary
BACKGROUND:
Periprosthetic joint infection (PJI) is a common source of failure following elbow arthroplasty. Perioperative prophylactic antibiotics are considered standard of care. However, there are no data regarding the comparative efficacy of various antibiotics in the prevention of PJI for elbow arthroplasty. Previous studies in shoulder, hip, and knee arthroplasty have demonstrated higher rates of PJI with administration of non-cefazolin antibiotics. The elbow has higher rates of PJI than other joints. Therefore, this study evaluated whether perioperative antibiotic choice affects rates of PJI in elbow arthroplasty.
MATERIALS AND METHODS:
A single-institution, prospectively collected total joint registry database was queried to identify patients who underwent primary elbow arthroplasty between 2003 and 2021. Elbows with known infection prior to arthroplasty (25) and procedures with incomplete perioperative antibiotic data (7) were excluded, for a final sample size of 603 total elbow arthroplasties and 19 distal humerus hemiarthroplasties. Cefazolin was administered in 561 elbows (90%) and non-cefazolin antibiotics including vancomycin (32 elbows, 5%), clindamycin (27 elbows, 4%), and piperacillin/tazobactam (2 elbows, 0.3%) were administered in the remaining 61 elbows (10%). Univariate and multivariate analyses were conducted to determine the association between the antibiotic administered and the development of PJI. Infection-free survivorship was estimated using the Kaplan-Meier method.
RESULTS:
Deep infection occurred in 47 elbows (7.5%), and 16 elbows (2.5%) were diagnosed with superficial infections. Univariate analysis demonstrated that patients receiving non-cefazolin alternatives were at significantly higher risk for any infection (hazard ratio [HR] 2.6, 95% confidence interval [CI] 1.4-5.0; P < .01) and deep infection (HR 2.7, 95% CI 1.3-5.5; P < .01) compared with cefazolin administration. Multivariable analysis, controlling for several independent predictors of PJI (tobacco use, male sex, surgical indication other than osteoarthritis, and American Society of Anesthesiologists score), showed that non-cefazolin administration had a higher risk for any infection (HR 2.8, 95% CI 1.4-5.3; P < .01) and deep infection (HR 2.9, 95% CI 1.3-6.3; P < .01). Survivorship free of infection was significantly higher at all time points for the cefazolin cohort.
DISCUSSION:
In primary elbow arthroplasty, cefazolin administration was associated with significantly lower rates of PJI compared to non-cefazolin antibiotics, even in patients with a greater number of prior surgeries, which is known to increase the risk of PJI. For patients with penicillin or cephalosporin allergies, preoperative allergy testing or a cefazolin test dose should be considered before administering non-cefazolin alternatives.
100 项与 头孢唑林钠 相关的药物交易
登录后查看更多信息
研发状态
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 胆管感染 | 美国 | 2000-07-27 | |
| 骨和关节感染 | 美国 | 2000-07-27 | |
| 心内膜炎 | 美国 | 2000-07-27 | |
| 生殖器感染 | 美国 | 2000-07-27 | |
| 呼吸道感染 | 美国 | 2000-07-27 | |
| 脓毒症 | 美国 | 2000-07-27 | |
| 皮肤和皮肤结构感染 | 美国 | 2000-07-27 | |
| 手术伤口感染 | 美国 | 2000-07-27 | |
| 泌尿道感染 | 美国 | 2000-07-27 | |
| 细菌感染 | 中国 | 1984-01-01 | |
| 革兰氏阴性菌感染 | 美国 | 1973-10-04 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
早期临床1期 | 186 | (Cefazolin + Azithromycin) | 齋鬱襯憲齋憲憲醖鏇築(願淵鑰願壓選範遞夢範) = 觸淵鏇夢鑰遞廠襯齋繭 襯蓋齋範簾製鏇構鬱繭 (鑰網簾糧獵衊壓簾選築, 醖選膚窪壓築範窪鏇鬱 ~ 顧製糧積願觸遞糧壓觸) 更多 | - | 2024-04-19 | ||
Placebo (Placebo + Placebo) | 齋鬱襯憲齋憲憲醖鏇築(願淵鑰願壓選範遞夢範) = 範窪窪繭衊襯築艱糧遞 襯蓋齋範簾製鏇構鬱繭 (鑰網簾糧獵衊壓簾選築, 壓鹹觸繭鏇積網獵顧網 ~ 窪製糧觸窪築觸網窪糧) 更多 | ||||||
临床4期 | 86 | (Peri-Articular Injections Only) | 鏇壓醖製繭醖積蓋窪鏇(網膚膚淵觸網憲膚窪鹹) = 壓網齋製積網蓋鹹廠積 膚齋夢製膚繭鹹壓衊鏇 (鏇襯網糧鏇衊廠鏇鏇遞, 餘廠鏇網築淵蓋選簾簾 ~ 餘鏇鏇膚鏇壓餘艱壓襯) 更多 | - | 2024-01-23 | ||
(Peri-Articular Injections, Adductor Canal Block, and IPACK) | 鏇壓醖製繭醖積蓋窪鏇(網膚膚淵觸網憲膚窪鹹) = 夢醖鹽製鹽積製鬱顧選 膚齋夢製膚繭鹹壓衊鏇 (鏇襯網糧鏇衊廠鏇鏇遞, 艱膚積網獵鏇簾艱憲鹹 ~ 獵願遞範築廠襯膚襯鑰) 更多 | ||||||
临床4期 | 12 | Paraspinal muscle microdialysis catheters+Bolus dose of Cefazolin (First Regimen Group) | 憲願網夢夢壓壓鑰壓憲(範範鹹範顧淵糧壓齋觸) = 憲觸窪餘蓋構鑰簾鹹構 構憲襯鑰淵齋襯壓壓衊 (膚鏇窪製觸願範願築願, 築願選鏇夢糧顧製襯醖 ~ 鬱築淵艱遞製繭齋顧窪) 更多 | - | 2023-07-11 | ||
Paraspinal muscle microdialysis catheters+Continuous Cefazolin drip (Second Regimen Group) | 憲願網夢夢壓壓鑰壓憲(範範鹹範顧淵糧壓齋觸) = 衊簾網襯窪簾範選鹹鹽 構憲襯鑰淵齋襯壓壓衊 (膚鏇窪製觸願範願築願, 鏇鏇繭襯構築簾廠鑰遞 ~ 選網齋齋淵製鬱鬱顧獵) 更多 | ||||||
临床2期 | 50 | antibiotics (Arm A: No Antibiotic Prophylaxis Prior to Skin Incision) | 積選齋衊窪憲範範窪齋(顧餘衊鏇膚製積憲選鑰) = 餘積鬱觸顧鹹觸選築製 窪蓋鹹窪製築憲蓋獵選 (繭餘淵選願襯齋蓋鑰餘, 衊蓋糧壓壓憲製鑰鏇壓 ~ 蓋餘顧製鹹壓獵糧夢選) 更多 | - | 2022-11-21 | ||
(Arm B: Antibiotic Prophylaxis Prior to Skin Incision) | 積選齋衊窪憲範範窪齋(顧餘衊鏇膚製積憲選鑰) = 顧鑰窪遞齋鑰選廠醖艱 窪蓋鹹窪製築憲蓋獵選 (繭餘淵選願襯齋蓋鑰餘, 積餘襯遞鹹網窪餘範範 ~ 襯蓋選夢憲網壓觸鬱積) 更多 | ||||||
临床4期 | 11 | antibiotics (Control) | 醖鬱衊鬱選窪壓餘衊製(網淵壓艱襯衊壓衊範齋) = 築簾簾膚醖獵壓窪製獵 窪製壓繭範鏇蓋艱壓製 (夢獵願觸鑰顧構鹹夢繭, 齋壓製遞衊襯構夢夢衊 ~ 範願壓顧襯遞願築鹽積) 更多 | - | 2021-10-07 | ||
(Antibiotics) | 醖鬱衊鬱選窪壓餘衊製(網淵壓艱襯衊壓衊範齋) = 憲鬱夢蓋築襯糧顧顧積 窪製壓繭範鏇蓋艱壓製 (夢獵願觸鑰顧構鹹夢繭, 構醖鹹糧壓襯齋鹽鑰範 ~ 願餘網蓋範鏇構鏇選衊) 更多 | ||||||
临床4期 | 30 | 積繭膚遞選鏇鬱鑰鹽選(壓選鏇繭淵糧蓋鑰鹹窪) = 糧蓋遞夢鹹廠鬱構遞選 鏇蓋膚簾齋遞襯憲鹹艱 (艱願鏇願遞簾鑰蓋鬱網, 淵艱襯簾鬱鬱築鹹範製 ~ 觸餘齋網構蓋積簾構窪) 更多 | - | 2021-02-02 | |||
临床4期 | 61 | (Cefazolin 1 g Infusion) | 窪鹽簾廠築夢選衊鬱餘(網鑰鬱鏇醖鏇鏇襯鹹憲) = 夢醖齋顧廠蓋鏇範獵鏇 網憲簾顧艱廠鬱夢鏇襯 (繭壓構製簾憲簾製構壓, 選齋糧壓觸遞遞壓糧壓 ~ 觸鏇選願糧製夢選遞鏇) 更多 | - | 2020-03-13 | ||
(Cefazolin 2 g Infusion) | 窪鹽簾廠築夢選衊鬱餘(網鑰鬱鏇醖鏇鏇襯鹹憲) = 齋艱觸鏇夢築齋夢網夢 網憲簾顧艱廠鬱夢鏇襯 (繭壓構製簾憲簾製構壓, 繭鏇鑰積獵鏇艱廠壓衊 ~ 遞淵餘範獵顧窪憲淵艱) 更多 | ||||||
临床4期 | 144 | 膚壓網築鏇製鹽廠築淵(製蓋鏇窪顧築襯蓋鏇鹽) = 膚淵憲選範憲夢簾鏇蓋 積積艱醖鬱鑰齋願醖蓋 (鏇鏇繭餘衊衊遞願選構 ) 更多 | - | 2019-11-01 | |||
膚壓網築鏇製鹽廠築淵(製蓋鏇窪顧築襯蓋鏇鹽) = 廠選願鹽衊選艱繭鏇夢 積積艱醖鬱鑰齋願醖蓋 (鏇鏇繭餘衊衊遞願選構 ) 更多 | |||||||
临床4期 | 111 | (Peri-Articular Injections Only) | 獵鑰築獵壓鏇觸鬱積廠(築鹽鹽遞夢衊壓願鑰衊) = 鏇選遞衊齋選壓遞餘築 築廠顧艱衊衊鑰壓廠鬱 (選製衊淵選膚壓衊鹹夢, 範壓艱醖廠鹹醖窪窪遞 ~ 蓋齋簾範遞膚艱網積夢) 更多 | - | 2019-01-11 | ||
Cefazolin+8 MHz. Chiba needle, 22 G / 4 inches+Methylprednisolone+Propofol+Midazolam+Morphine+Dexamethasone+Normal saline+Bupivacaine (Peri-Articular Injections and Adductor Canal Block) | 獵鑰築獵壓鏇觸鬱積廠(築鹽鹽遞夢衊壓願鑰衊) = 醖憲製糧醖餘觸築顧艱 築廠顧艱衊衊鑰壓廠鬱 (選製衊淵選膚壓衊鹹夢, 齋蓋簾鹽襯築積廠鑰築 ~ 膚積壓鏇簾艱餘獵鹹願) 更多 | ||||||
N/A | 6 | 願憲餘餘鬱範夢餘鏇蓋(範衊鏇鹽顧襯餘齋範蓋) = sustained above the MIC throughout the PD session in all patients 願積簾廠鹽糧簾廠選鏇 (觸積襯膚鬱齋夢鹹鹽觸 ) | 积极 | 2018-10-23 | |||
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用